The product does not meet quality requirements due to a negative test result for the particle size analysis parameter, which is critical for the safety and efficacy of an injectable suspension. Potencjalne skutki: lack of treatment efficacy, adverse reactions, complications after injection.
Download the app and stay informed
Get instant notifications about recalled products and protect your family.
Important Information
Do not use this medicinal product; patients should consult a doctor or pharmacist to obtain alternative therapy and check whether the product they hold is subject to the suspension of distribution.
The Chief Pharmaceutical Inspector suspended the distribution of the medicinal product Egoropal (Paliperidone), prolonged-release suspension for injection, 75 mg, throughout the country and granted th...
If you feel unwell after consuming this product, contact your doctor or call the poison control center.
FAQ
Related